These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31795962)

  • 21. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry.
    Choi J; Jung WH; Koo JS
    Pathobiology; 2013; 80(1):41-52. PubMed ID: 22832328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
    Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
    Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.
    Hektoen HH; Flatmark K; Andersson Y; Dueland S; Redalen KR; Ree AH
    BMC Cancer; 2015 Jul; 15():543. PubMed ID: 26205955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
    Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
    Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.
    Gunawan I; Hatta M; Benyamin AF; Islam AA
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):629-637. PubMed ID: 32212787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
    Brown-Glaberman U; Marron M; Chalasani P; Livingston R; Iannone M; Specht J; Stopeck AT
    Dis Markers; 2016; 2016():9810383. PubMed ID: 26941473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
    Peterle GT; Maia LL; Trivilin LO; de Oliveira MM; Dos Santos JG; Mendes SO; Stur E; Agostini LP; Rocha LA; Moysés RA; Cury PM; Nunes FD; Louro ID; Dos Santos M; da Silva AMÁ
    J Oral Pathol Med; 2018 Jul; 47(6):566-574. PubMed ID: 29693741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
    Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
    Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma.
    Sukeda A; Nakamura Y; Nishida Y; Kojima M; Gotohda N; Akimoto T; Ochiai A
    Pancreas; 2019 Sep; 48(8):1102-1110. PubMed ID: 31404019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.
    Choi JW; Kim Y; Lee JH; Kim YS
    Urology; 2014 Jul; 84(1):245.e9-15. PubMed ID: 24857275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry.
    Liao ND; Shieh JM; Lee WY
    Cancer Cytopathol; 2011 Oct; 119(5):346-53. PubMed ID: 21442770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.